Viking Therapeutics, Inc. Current Assets
Viking Therapeutics, Inc. (VKTX) had Current Assets of $517.56 million as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-07-29
- 2026-06-30: Assets, Current $517.56M.
- 2026-03-31: Assets, Current $608.21M.
- 2025-12-31: Assets, Current $715.60M.
- 2025-09-30: Assets, Current $738.70M.
| Period end | Assets, Current | Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $517.56M 10-Q · filed 2026-07-29 | |
| 2026-03-31 | $608.21M 10-Q · filed 2026-04-30 | |
| 2025-12-31 | $715.60M 10-Q · filed 2026-07-29 | |
| 2025-09-30 | $738.70M 10-Q · filed 2025-10-23 | |
| 2025-06-30 | $827.02M 10-Q · filed 2025-07-23 | |
| 2025-03-31 | $866.02M 10-Q · filed 2025-04-24 | |
| 2024-12-31 | $907.22M 10-K · filed 2026-02-11 | |
| 2024-09-30 | $936.65M 10-Q · filed 2024-10-23 | |
| 2024-06-30 | $945.72M 10-Q · filed 2024-07-24 | |
| 2024-03-31 | $966.34M 10-Q · filed 2024-04-25 | |
| 2023-12-31 | $367.23M 10-K · filed 2025-02-26 | |
| 2023-09-30 | $381.30M 10-Q · filed 2023-10-25 | |
| 2023-06-30 | $399.37M 10-Q · filed 2023-07-26 | |
| 2023-03-31 | $149.47M 10-Q · filed 2023-04-26 | |
| 2022-12-31 | $167.04M 10-K · filed 2024-02-07 | |
| 2022-09-30 | $165.15M 10-Q · filed 2022-10-26 | |
| 2022-06-30 | $179.86M 10-Q · filed 2022-07-27 | |
| 2022-03-31 | $193.30M 10-Q · filed 2022-04-27 | |
| 2021-12-31 | $210.53M 10-K · filed 2023-02-10 | |
| 2021-09-30 | $224.28M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $237.66M 10-Q · filed 2021-07-28 | |
| 2021-03-31 | $249.86M 10-Q · filed 2021-04-28 | |
| 2020-12-31 | $256.10M 10-K · filed 2022-02-09 | |
| 2020-09-30 | $263.13M 10-Q · filed 2020-10-28 | |
| 2020-06-30 | $270.62M 10-Q · filed 2020-07-29 | |
| 2020-03-31 | $276.45M 10-Q · filed 2020-04-30 | |
| 2019-12-31 | $283.50M 10-K · filed 2021-02-17 | |
| 2019-09-30 | $289.26M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $293.64M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $299.14M 10-Q · filed 2019-05-02 | |
| 2018-12-31 | $302.13M 10-K · filed 2020-02-26 | |
| 2018-09-30 | $306.62M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $144.26M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $78.73M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $21.85M 10-K · filed 2019-03-13 | $21.85M 10-K · filed 2018-03-07 |
| 2017-09-30 | $11.53M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $14.26M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $14.67M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $13.97M 10-K · filed 2018-03-07 | |
| 2016-09-30 | $15.62M 10-Q · filed 2016-11-10 | |
| 2016-06-30 | $18.31M 10-Q · filed 2016-08-11 | |
| 2016-03-31 | $12.16M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $15.20M 10-K · filed 2017-03-21 | |
| 2015-09-30 | $18.93M 10-Q · filed 2015-11-05 | |
| 2015-06-30 | $22.27M 10-Q · filed 2015-08-14 | |
| 2015-03-31 | $360.40K 10-Q · filed 2015-06-12 | |
| 2014-12-31 | $773.68K 10-K · filed 2016-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |